Four new antimalarial drugs are expected to reach sub-Saharan Africa within the next three years, according to the nonprofit Medicines for Malaria Venture (MMV).
"It is urgent for us to plan the launch of these new drugs and ensure that they reach those desperately in need," noted Christopher Hentschel, CEO of the MMV. "We must mobilize all necessary talents and resources, because winning the battle against malaria is within our reach."
MMV manages the largest global portfolio of malaria drug research, with over 20 projects underway, all in various stages of research and development, added Hentschel. The organization plans to register at least one new antimalarial drug before 2010, with the hope of maintaining a sustainable output of drugs to service the 2.4 billion people at risk of the disease.
The specific antimalarials in development were not reported.
